INTRODUCTION: African Americans have a greater incidence of @entity2 than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed- @entity3003 -bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. @entity1311 - @entity3003 -bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the @entity1 were African American. PointBreak had negative findings; PemCBev did not demonstrate superior @entity1349 ( @entity1349 ). MATERIALS AND METHODS: PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and @entity4207 versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. RESULTS: Of 939 intent-to-treat (ITT) @entity1 , 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, @entity1349 (HR, 1.125; P  = .525), progression-free survival (PFS) (HR, 1.229; P  = .251), response (P  = .607), and @entity137 profiles were similar in African Americans versus whites. For African Americans, @entity1349 (HR, 1.375; P  = .209), PFS (HR, 0.902; P  = .670), response (P  = 1.000), and @entity137 profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in @entity1349 (HR, 0.661; P  = .191) or PFS (HR, 0.969; P  = .915) in @entity4207 versus community practice settings. CONCLUSION: In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or @entity137 profiles. Consistent with the ITT population negative trial result, for African Americans, the median @entity1349 was not superior for either arm. For African Americans, PFS and @entity1349 were similar in the  @entity4207 and community settings. Additional outcomes data for African Americans should be collected in @entity2 studies.

Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed- @entity3003 -Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus @entity1311 - XXXX -Bevacizumab Followed by  Maintenance Bevacizumab in @entity1 With Stage IIIB/IV Nonsquamous Non-Small-Cell @entity2 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity4207 :: ('MESH:D007859', 'Disease') :: ['academic'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity3003 :: (MESH:D016190,Chemical) :: ['Carboplatin']
